Modeling NKG2D-based CAR-T cell therapy in animals with acute myeloid leukemia

Modeling NKG2D-based CAR-T cell therapy in animals with acute myeloid leukemia

Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Updated results from Phase I trials assessing a NKG2D CAR T-cell approach in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients

Development of a next generation allogeneic CAR-T cell platform without gene editing

Development of a next generation allogeneic CAR-T cell platform without gene editing

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-based CAR-T Therapy, CYAD-01, in Acute Myeloid Leukemia

Differential effects of target ligands upon NKG2D CAR T cell activation

Differential effects of target ligands upon NKG2D CAR T cell activation

Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

Endogenous DAP10 provides optimal co‐stimulation for NKG2D‐based CARs

Overcoming target‐driven fratricide for CAR‐T cell therapy

Overcoming target‐driven fratricide for CAR‐T cell therapy

Functional screening of different anti-B7H6 CAR designs

Functional screening of different anti-B7H6 CAR designs

Generating Allogeneic CAR T cells without Gene Editing

Generating Allogeneic CAR T cells without Gene Editing

Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors

Results and perspectives from Phase 1 studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic solid tumors

The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo

The co-expression of a single shRNA targeting MICA and MICB with a NKG2D CAR generates CAR-T cells resistant to target driven fratricide and improves CAR T cell persistence in vivo

CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule

CYAD-101: an allogeneic NKG2D CAR T cell therapy using a TCR inhibitory molecule